Description
The abstract identifies the need for proteomic and metabolomic profiling to identify at-risk patients, but specific molecular signatures remain unknown. Identifying these biomarkers could enable early intervention before irreversible neurodegeneration occurs.
Gap type: open_question Source paper: The diagnostic potential of fluid and imaging biomarkers in chronic traumatic encephalopathy (CTE). (2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, PMID:35062068)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:49.081689+00:00”, “resolution_summary”: “Resolved by hypothesis h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27: CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27”, “title”: “CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration”, “score”: 0.234, “reason”: “5 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-26-gap-20260426-001521”, “target_gene”: “AQP4”, “target_pathway”: null, “disease”: null, “composite_score”: 0.7050000000000001, “confidence_score”: 0.498, “status”: “proposed”, “pubmed_evidence_ids”: [“24179313”, “27371494”, “30561329”, “30842439”, “34499128”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446”, “title”: “The abstract explicitly states the critical need to identify genetic risk factors for CTE, but these remain unknown. Understanding genetic susceptibility could enable risk stratification and personalized prevention strategies for athletes and military personnel.\n\nGap type: open_question\nSource paper: The neuropathology of chronic traumatic encephalopathy. (2015, Brain pathology (Zurich, Switzerland), PMID:25904048)”, “score”: 0.638, “reason”: “15 token overlaps; entity overlap: cte, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446”, “quality_score”: 0.58, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184233-98bf553f”, “title”: “The observation that salsalate and diflunisal decrease both AD and TBI incidence suggests these drugs may prevent injury occurrence, not just treat consequences. This unexpected finding challenges the assumed mechanism of action and has major therapeutic implications.\n\nGap type: unexplained_observation\nSource paper: Reducing acetylated tau is neuroprotective in brain injury. (2021, Cell, PMID:33852912)”, “score”: 0.375, “reason”: “5 token overlaps; entity overlap: pmid, tbi”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184233-98bf553f”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47”, “title”: “While the abstract mentions identifying subcellular roles of protein interactions, the mechanistic principles governing how interaction networks specify subcellular function remain unclear. This knowledge gap limits our ability to predict how disease mutations disrupt cellular compartmentalization in neurons.\n\nGap type: open_question\nSource paper: A reference map of the human binary protein interactome. (2020, Nature, PMID:32296183)”, “score”: 0.359, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.355, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.343, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}